ReviewZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2026
[Alcohol liver disease: immunoregulatory mechanisms and precision therapeutic targets].
Review in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Alcohol liver disease (ALD) represents a major health challenge worldwide, with particularly high mortality in severe alcohol-associated hepatitis. Inflammation plays a central role in ALD progression, and immune cells along with their inflammatory mediators contribute to disease development through actions in both the liver and extrahepatic organs. Currently, there is a lack of targeted therapies that can effectively block chronic ALD progression or intervene in alcohol-related acute liver failure. This article elucidates the core mechanisms by which immune heterogeneity drives the development and progression of ALD and influences treatment responses, summarizes current clinical research progress in anti-inflammatory therapies, and highlights promising future directions, particularly biomarker-guided precision therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.